Organ-on-a-Chip Resources

Vox Pop Pharma – companies keen to find alternatives to animal testing – read their views

Earlier this week, Charles River Laboratories International, Inc. revealed its Alternative Methods Advancement Project (AMAP), which it said is a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing.

Next Generation Drug Discovery: Bridging the Gap with Organ-on-a-Chip Technology

In today’s drug development landscape, there is a critical need for more human-relevant preclinical testing models. Traditional in vitro assays and in vivo animal models often fall short in predicting human outcomes, especially as advanced drug modalities with human-specific actions become more prevalent. Organ-on-a-Chip (OOC) technology, a groundbreaking solution designed to replicate human physiology and function in vitro, offers a promising path forward.

A Gut/Liver microphysiological system for profiling human oral bioavailability

Webinar Series 7 Episode 4

Explore how the innovative Gut/Liver microphysiological system (MPS) enhances in vitro ADME profiling by linking primary human intestinal and liver cells to predict human drug bioavailability more accurately. This webinar demonstrates improved predictive capacity for complex drug behaviors, advancing drug discovery and safety assessment.

Evaluating Caco-2 cell’s gold-standard status in absorption, permeability and bioavailability Studies: Are Their Limitations Justified?

In the realm of pharmaceutical research, Caco-2 cells have long been heralded as the gold standard for studying intestinal absorption and permeability.

Go/No-Go

Webinar Series 7 Episode 3

In this webinar, we demonstrate how to further de-risk your workflows with the PhysioMimix^® DILI assay. Using drugs that were identified as toxic in the clinic, we reveal some of the data-rich investigative toxicology studies that can be achieved using a human liver microphysiological system (MPS), otherwise known as organ-on-a-chip (OOC).

User Group Meeting 2024 – Recap

October 17, 2024, marked a milestone for CN Bio as we hosted our inaugural virtual conference and User Group Meeting (UGM).

Designed specifically for our customers, partners, collaborators, and those looking for practical insights into Organ-on-a-chip (OOC) adoption, the event showcased the transformative power of OOC in drug development and research.

Lost in Translation

Webinar Series 7 Episode 2

This MPS webinar explores how you can improve your clinical translation by applying microphysiological systems (MPS) / Organ-on-a-chip (OOC) to bridge the gap between preclinical research and clinical trials. Discover how MPS/OOC improve drug candidate assessment by generating physiologically relevant data, reduce DILI risks, and accelerate drug development.

Bridging the gap

Drug-induced liver injury (DILI) remains the most common cause for acute liver failure in the world and is a leading cause of compound attrition in drug discovery. Although sufficient at capturing most intrinsic events, current models used in drug discovery have limitations as they are not effective at predicting or understanding more complex DILI events in humans. Furthermore, for testing new human-specific modalities, cell lines/animal models are less suitable due to genetic or immunological response differences. Using the PhysioMimix® Organ-on-a-Chip (OOC) System, human and preclinical animal microphysiological system (MPS) models have been developed to bridge these gaps.

6 Challenges in ADME Drug Development

Explore the current challenges in profiling preclinical human ADME through key publications. Can advances in the human relevance of preclinical models improve estimations for safer and more efficient drug development?

Organ-on-a-Chip: Big Questions Surrounding Regulation and the Roadmap to Broad Adoption

Webinar Series 7 Episode 1

To enhance and modernize the drug development process, many organizations are adopting Organ-on-a-chip (OOC) technologies into their workflows, from efficacy to safety assessment. With evolving developments in the technology and its applications, questions and opportunities are arising, especially with regards to the regulatory landscape for NAMs, cost efficiency, and model confidence through standardization.

Liver-on-chip model and application in predictive genotoxicity and mutagenicity of drugs

Kopp et al., 2024. Current pre-clinical drug safety assessments lack a single, comprehensive test system for genotoxicity hazards identification. This study, aimed to develop an in vitro model to addresses this gap, looks at Organ-on-a-chip (OOC) technology as a solution. OOC present robust human metabolic activity and has the potential to assess all required endpoints for genotoxicity hazards identification, ultimately streamlining the process and eliminating the need for animal testing. This proof-of-concept experiment demonstrates the potential of PhysioMimix^® Liver-on-a-chip model as a promising tool for in vitro genotoxicity hazards identification, paving the way for a more streamlined and animal-free pre-clinical drug safety assessment process.

Defining validation criteria for a primary jejunum and primary hepatocyte dual-organ MPS

Improve in vitro to in vivo data translation for drug safety and efficacy with our fluidically-linked dual-organ MPS (microphysiological system); combining two well-characterized human Gut/Liver MPS – the RepliGut^® Jejunum and PhysioMimix® Liver MPS, in an interconnected model suitable for enhanced bioavailability profiling.